Please assess the completion status of the following clinical trial:

Trial Title: NewBreez for Airway Protection in Head and Neck Cancer Patients With Chronic Aspiration

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* History of head and neck cancer~* Chronic aspiration~* Currently has a tracheostomy~* Patient is able to independently maintain their tracheostomy and cannula apparatus~* Patient meets the CE Mark indications and are not contraindicated for a NewBreez procedure.~* Anatomically compatible with the available sizes of NewBreez®~* 18 years of age or older~* Sufficient cognitive function to comply with the study and follow-up requirements~* Patient gives voluntary signed informed consent~Exclusion Criteria:~* Recurrent or present cancer in the previous 12 months~* Absent cough reflex~* Severely disrupted swallowing function e.g. severe neurological deficit, absent swallowing reflex, severe fixation of the larynx due to scarring with absent elevation of the larynx~* Upper esophageal sphincter not functional e.g. remains closed~* Cor Pulmonale / Pulmonary Heart Disease, or current lung infection~* Mouth opening less than 3.5cm~* Neck extension severely restricted hindering implantation of the device~* Contraindication to general anesthesia~* Severe hyperostosis (spondylophytes) of the cervical vertebrae causing dysphagia~* Severe (radiogenic) edema or damage of the mucosa of the upper aerodigestive tract

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NewBreez (Type: None): The study group is composed only of patients who have already opted to receive the NewBreez device as part of their routine care from their physician.~Patients who have the device implanted, and consent to be part of the 12 week observational study, will be enrolled and have standard clinical parameters measured over the 12 week period as well as complete quality of life assessments in the form of patient questionnaires.

Based on this trial design, predict the completion outcome and termination type (if applicable).